Moffitt logo

IAN STORM UPDATE: Moffitt Cancer Center is open for normal business. Storm preparations

Articles related to CAR T

Cell Therapies 640

Cellular Immunotherapy Highlights from ASCO

Moffitt’s physicians and scientists were proud to share and present their cellular immunotherapy research findings at American Society of Clinical Oncology (ASCO 2022) Read More


CART-Cell-Illustration-640.jpg

New Study Finds "Off the Shelf CAR-T" Promising for Certain Lymphoma Patients

Moffitt is one of a few hospitals nationwide testing ALLO-501a, an allogeneic CAR T therapy product from Allogene Therapeutics, in combination with ALLO-64 Read More


DNA-Genetic-Mutation.jpg

Comprehensive Molecular Profiling of Undifferentiated Embryonal Sarcoma of the Liver

Moffitt Cancer Center is leading the research in rare sarcomas and has performed the most comprehensive molecular analysis to-date of undifferentiated embryonal sarcoma of the liver Read More


lung-screening-information.jpg

Reshaping the Frontline Treatment Landscape of ES-SCLC

Dr. Bruna Pellini, in an interview with OncLive®, also compares the findings of the CASPIAN and IMpower133 trials and research efforts currently ongoing in ES-SCLC Read More


Moffitt Cancer Center Thoracic 13

Improving Representation of Racial and Ethnic Minorities in Lung Cancer Screening Programs

With recent screening guidelines changes, more people are eligible for a low-dose CT scan and have the ability to participate in lung screening programs or trials. Read More


Research-Programs.jpg

CAR T Clinical Trials for Multiple Myeloma Bring Promising New Treatments

Moffitt researchers are leaders in advancing the field of CAR T therapy and multiple myeloma clinical trials provide patients with exciting new treatment opportunities. Read More


Locke-research-lab.jpg

Moffitt’s Top Research Developments of 2017: CAR T Therapy Tested, Commercially Available at Moffitt

The first one on the list of Moffitt's top research developments for 2017 is the FDA approval of CAR T therapy for certain aggressive types of adult lymphoma. Read More


CART-Cell-Illustration-640.jpg

Moffitt Treats First U.S. Patient with Newly FDA-Approved CAR T Therapy

Moffitt has treated the first U.S. adult lymphoma patient with a therapy formerly available only through clinical trials. Read More


CART-teaser.jpeg

Infographic: How CAR T Therapy Works to Fight Cancer

CAR T therapy, a groundbreaking new treatment, utilizes the body’s own immune system to fight cancer. Read More


CART-lab-640.jpg

What is CAR T Therapy?

Dr. Frederick Locke, vice chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy, answers some frequently asked questions about CAR T cell therapy. Read More


DrFredLocke-CART-640.jpg

CAR T Cancer Therapy a ‘Huge Breakthrough’ for Patients with Lymphoma

Moffitt patients with an aggressive type of lymphoma were among the first to benefit in clinical trials of a groundbreaking therapy. Read More


Locke-blog.jpg

Dr. Locke: CAR-T Cell Therapy a 'Revolution in Cancer Care'

Dr. Locke, the principal investigator for a new experimental immunotherapy called CAR T-cell therapy, talks about the breakthroughs with this type of treatment. Read More